St. Jude Medical (STJ) PT Lifted to $82 at Wedbush Following Strong Q1

Wedbush analyst Tao Levy reiterated an Outperform rating and raised his price target on St. Jude Medical (NYSE: STJ) to $82.00 (from $77.00) following "impressive" Q1 results.

Levy commented, "Impressive 1Q results for St. Jude Medical, driven by CardioMEMS, Atrial Fibrillation, and Neuromodulation; bodes well for the remainder of 2015. With investor concerns surrounding STJ's ability to retain US ICD market share, STJ delivered and put these concerns to rest. Given the positive uptake of its recently launched products and a healthy cadence of expected product launches, we reiterate our positive long-term thesis on STJ."

For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.

Shares of St. Jude Medical closed at $73.55 yesterday.

You May Also Be Interested In

• Berenberg Upgrades STMicroelectronics NV (STM:FP) (STM) to Buy
• Morgan Stanley Upgrades Galp Energia (GALP:SM) (GLPEY) to Equalweight
• Reliance Industries (RIL:IN) PT Raised to INR2,770 at HSBC